Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) announced the initiation of process development and intermediate scale-up activities for A83B4C63, the active pharmaceutical ingredient in its proprietary drug candidate ONC010. The work represents a key milestone in the company’s chemistry, manufacturing and controls strategy as it advances toward IND-enabling studies and planning for first-in-human clinical evaluation.
The program will focus on optimizing synthetic processes, improving yield and reproducibility and scaling production of key intermediates required for downstream manufacturing and formulation. The effort will be conducted in collaboration with Dalton Pharma Services and is intended to establish a robust, scalable manufacturing process capable of supporting continued preclinical development, regulatory readiness and future clinical supply requirements. This announcement is critical for Onco-Innovations as it moves closer to bringing ONC010 to clinical trials, potentially offering a new treatment option for solid tumors.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. The company’s mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. It has secured an exclusive worldwide license to patented technology that targets solid tumours. The advancement of ONC010 underscores the company’s commitment to addressing unmet medical needs in oncology. For more information, visit https://oncoinnovations.com/.
The full press release can be viewed at https://nnw.fm/kfFWv. This development highlights the importance of robust manufacturing processes in the drug development pipeline, as they are essential for consistent product quality and regulatory approval. Onco-Innovations’ focus on process optimization and scale-up is a strategic move to de-risk future clinical trials and ensure supply chain reliability.
